Literature DB >> 14062490

THE RESPONSE OF EXPERIMENTALLY INDUCED MAMMARY TUMOURS IN RATS TO HYPOPHYSECTOMY AND TO PITUITARY STALK SECTION.

P M DANIEL, M M PRICHARD.   

Abstract

Entities:  

Keywords:  EXPERIMENTAL LAB STUDY; HYPOPHYSECTOMY; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS

Mesh：

Year:  1963        PMID： 14062490      PMCID： PMC2071029          DOI： 10.1038/bjc.1963.59

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  4 in total

1.  The volumes of pars distalis, pars intermedia and infundibular process of the pituitary gland of the rat, with special reference to the effect of stalk section.

Authors:  J H ADAMS; P M DANIEL; M M PRICHARD
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1963-07

2.  Interruption of the pituitary stalk in the patient with mammary cancer.

Authors:  G EHNI; N E ECKLES
Journal:  J Neurosurg       Date:  1959-11       Impact factor: 5.115

3.  Mammary carcinogenesis by 3-methylcholanthrene. I. Hormonal aspects in tumor induction and growth.

Authors:  T L DAO; H SUNDERLAND
Journal:  J Natl Cancer Inst       Date:  1959-09       Impact factor: 13.506

4.  The hypophysial portal system of vessels in man.

Authors:  G P XUEREB; M L PRICHARD; P M DANIEL
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1954
  4 in total
  5 in total

1.  Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.

Authors:  T Reissmann; P Hilgard; J H Harleman; J Engel; A M Comaru-Schally; A V Schally
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.

Authors:  T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

3.  Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations.

Authors:  K Stoeckemann; J Sandow
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Endocrine differences between rats bearing simple and malignant mammary tumours induced by 9,10-dimethyl-1,2-benzanthracene.

Authors:  T Hamilton; A Sneddon
Journal:  Br J Cancer       Date:  1968-06       Impact factor: 7.640

5.  Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.

Authors:  R I Nicholson; P V Maynard
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.